Edition:
United States

BioCryst Pharmaceuticals Inc (BCRX.O)

BCRX.O on Nasdaq

8.78USD
24 Mar 2017
Change (% chg)

$0.29 (+3.47%)
Prev Close
$8.49
Open
$8.61
Day's High
$8.87
Day's Low
$8.52
Volume
967,338
Avg. Vol
1,485,890
52-wk High
$9.25
52-wk Low
$2.48

BCRX.O

Chart for BCRX.O

About

BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular... (more)

Overall

Beta: 3.41
Market Cap(Mil.): $696.77
Shares Outstanding(Mil.): 79.31
Dividend: --
Yield (%): --

Financials

  BCRX.O Industry Sector
P/E (TTM): -- 47.98 29.94
EPS (TTM): -0.75 -- --
ROI: -115.38 -2.56 13.01
ROE: -223.70 5.14 14.16

BRIEF-Biocryst Pharma commences public offering of common stock

* Biocryst Pharmaceuticals commences public offering of common stock

Mar 08 2017

BRIEF-D. E. Shaw & Co reports 5 pct passive stake in Biocryst Pharmaceuticals as of Feb 23, 2017

* D. E. Shaw & Co, L.P. reports 5 percent passive stake in Biocryst Pharmaceuticals Inc as of Feb 23, 2017 -sec filing Source text (http://bit.ly/2mciI8d) Further company coverage:

Mar 06 2017

BRIEF-BioCryst Pharmaceuticals Q4 loss per share $0.06

* Biocryst reports fourth quarter and full year 2016 financial results

Feb 27 2017

BRIEF-Biocryst Pharmaceuticals reports positive interim results from APEX-1 trial

* Biocryst reports positive interim results from its Apex-1 trial

Feb 27 2017

BRIEF-Biocryst announces acceptance of Peramivir MAA filing by the European Medicines Agency

* Biocryst announces the acceptance of Peramivir MAA filing by the European Medicines Agency Source text for Eikon: Further company coverage:

Jan 30 2017

BRIEF-D. E. Shaw & Co reports 5 pct passive stake in Biocryst pharma- sec filing

* As of Jan 4 - D. E. Shaw & Co. L.P. Reports 5 Pct Passive Stake In Biocryst Pharmaceuticals Inc SEC filing Source text for Eikon: Further company coverage:

Jan 09 2017

BRIEF-Biocryst Q3 loss $0.16/shr

* Q3 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S

Nov 07 2016

BRIEF-Biocryst Pharmaceuticals closes $23 million senior credit facility

* Biocryst closes $23 million senior credit facility Source text for Eikon: Further company coverage:

Sep 26 2016

More From Around the Web

Competitors

Earnings vs. Estimates